Sinovac +5.3% AH. Trial results published in journal.

Phase III trial results for Sinovac's (SVA) EV71 vaccine have been published in the Feb. 27 issue of the New England Journal of Medicine. (PR)

Sinovac says the results show EV71 had a 94.8% efficacy rate against EV71-related hand, foot, and mouth disease, and a 100% efficacy rate "against EV71-associated hospitalization and against HFMD with neurologic complications."

From other sites
Comments (1)
  • winter999
    , contributor
    Comment (1) | Send Message
    great result and expect China FDA approve the product very soon
    27 Feb 2014, 12:54 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs